Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01748084
What this trial is testing

Rituximab in Systemic Sclerosis

Who this might be right for
Systemic Sclerosis
Assistance Publique - Hôpitaux de Paris 22
Large-scale testing (Phase 3)Looking for participantsNCT07188558
What this trial is testing

Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Who this might be right for
Large B-cell LymphomaLymphoma, B-CellRelapsed Non-Hodgkin Lymphoma+6 more
Lyell Immunopharma, Inc. 400
Early research (Phase 1)Study completedNCT00101829
What this trial is testing

Anti-CD20 Antibody Therapy for Sjogren's Syndrome

Who this might be right for
Sjogren's Syndrome
National Institute of Allergy and Infectious Diseases (NIAID) 12
Early research (Phase 1)Study completedNCT00354926
What this trial is testing

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Applied Molecular Evolution 67
Very early researchUnknownNCT04156178
What this trial is testing

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

Who this might be right for
B Cell LymphomaB Cell Leukemia
iCell Gene Therapeutics 12
Early research (Phase 1)Active Not RecruitingNCT04872790
What this trial is testing

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Who this might be right for
B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Mixed Phenotype Acute Leukemia+2 more
OHSU Knight Cancer Institute 20
Testing effectiveness (Phase 2)Study completedNCT01665768
What this trial is testing

Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

Who this might be right for
CD20+, B-cell LymphomasMantle Cell LymphomaNon-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL)+3 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 56
Not applicableEnded earlyNCT02844491
What this trial is testing

Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B

Who this might be right for
Hematological Malignancies B
Centre Hospitalier Universitaire de Besancon 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT03322865
What this trial is testing

Obinutuzumab in Marginal Zone Lymphoma

Who this might be right for
Marginal Zone Lymphoma
Christian Buske 56
Testing effectiveness (Phase 2)Study completedNCT00251394
What this trial is testing

Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Dana-Farber Cancer Institute 30
Early research (Phase 1)Ended earlyNCT04853329
What this trial is testing

Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

Who this might be right for
CD20 Positive Non Hodgkin Lymphoma
Conjupro Biotherapeutics, Inc. 7
Testing effectiveness (Phase 2)Study completedNCT00001337
What this trial is testing

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell LymphomaBurkitt Lymphoma+2 more
National Cancer Institute (NCI) 348
Testing effectiveness (Phase 2)Active Not RecruitingNCT05622201
What this trial is testing

Controlled Trial With Rituximab for Psychotic Disorder in Adults

Who this might be right for
Schizophrenia Spectrum and Other Psychotic Disorders
Region Örebro County 123
Testing effectiveness (Phase 2)Active Not RecruitingNCT05065554
What this trial is testing

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Who this might be right for
IgM MGUSWaldenstrom MacroglobulinemiaNeuropathy;Peripheral
Shayna Sarosiek, MD 12
Not applicableEnrolling By InvitationNCT06985576
What this trial is testing

Long-term Study to Evaluate Safety and Persistence of GF-CART01

Who this might be right for
DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma (FL)Primary Mediastinal Large B-Cell Lymphoma+1 more
GenomeFrontier Therapeutics TW Co., Ltd. 18
Testing effectiveness (Phase 2)UnknownNCT01429610
What this trial is testing

Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia

Who this might be right for
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asan Medical Center 78
Testing effectiveness (Phase 2)Ended earlyNCT02384954
What this trial is testing

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Who this might be right for
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Altor BioScience 43
Testing effectiveness (Phase 2)Study completedNCT00532129
What this trial is testing

MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.

Who this might be right for
Lymphocytic Leukemia, Chronic
Hoffmann-La Roche 100
Testing effectiveness (Phase 2)Ended earlyNCT00493454
What this trial is testing

Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 6
Early research (Phase 1)Study completedNCT02290951
What this trial is testing

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Who this might be right for
Non-Hodgkin LymphomaChronic Lymphocytic Leukemia
Regeneron Pharmaceuticals 200
Next Page